

## CURRICULUM VITAE

BRADLEY C. EKSTRAND, M.D., PH.D.

### CURRENT AFFILIATION:

California Cancer Care  
218 De Anza Blvd.  
San Mateo, CA 94402

Telephone: (650) 341-9131

### EDUCATION:

1990-1997 Yale University School of Medicine  
New Haven, Connecticut  
M.D.

1990-1997 Yale University School of Medicine  
Department of Pharmacology  
New Haven, Connecticut  
Ph.D., M.Phil.  
Faculty Advisor: Dr. Eric R. Fearon

1986-1990 Stanford University  
Palo Alto, California  
B.S. in Chemistry

### POST-DOCTORAL TRAINING:

2000-2003 Fellow in Medical Oncology  
Stanford University School of Medicine  
Stanford, California

1997-2000 Mount Sinai Medical Center  
New York, New York  
Internship and Residency in Internal Medicine

**ACADEMIC APPOINTMENTS:**

2003-present      Adjunct Clinical Instructor  
Division of Oncology, Department of Medicine  
Stanford University School of Medicine  
Stanford, CA

2002-2003      Staff Physician and Voluntary Clinical Faculty  
Department of Medicine, Division of Oncology  
Stanford University School of Medicine  
Stanford, CA

1999-2000      Teaching Assistant, Department of Medicine  
Mount Sinai School of Medicine  
New York, New York

**LICENSURE:**      California Certificate      April, 2000

**BOARD  
CERTIFICATION:**      American Board of Internal Medicine  
27 October 2000

**HONORS:**

June 1990      Phi Beta Kappa  
Stanford University

June 1990      B.S. in Chemistry with Honors and Distinction  
Stanford University

May 2001      Housestaff Teaching Award Nominee  
Department of Medicine  
Stanford University Medical School

March 2002      Postdoctoral Fellow Merit Award  
American Society of Clinical Oncology

**PROFESSIONAL SOCIETIES:**

2001 – present      American Society of Clinical Oncology  
Associate Member

**PROFESSIONAL EDUCATION:**

July 2002      Workshop on Methods in Clinical Cancer Research  
American Society of Clinical Oncology and  
American Association for Cancer Research  
Vail, Colorado

## TEACHING APPOINTMENTS:

Fall 1994                      Teaching Assistant, Upper Level Cell Biology course  
Department of Biology  
Yale College, New Haven, Connecticut  
Director: Prof. Joel Rosenbaum

## PUBLICATIONS:

**Ekstrand, B.C.**, Fan, Z., Lucas, J.B., Horwitz, S.M., Breslin, S., Natkunum, Y., Bartlett, N.L., Hoppe, R.T., and Horning, S.J. (2002) Rituximab in lymphocyte predominant Hodgkin's disease (LPHD): results of a phase II trial. *Blood* **101**: 4285-4289.

**Ekstrand, B.C.** and Horning, S.J. (2002) Lymphocyte predominant Hodgkin's disease. *Curr. Oncol. Rep.* **4**: 424-433.

**Ekstrand, B.C.** and Horning, S.J. (2002) Hodgkin's Disease. *Blood Reviews* **16**: 111-117.

Meyerhardt, J.A., Caca, K., **Ekstrand, B.C.**, Hu, G., Legnauer, C., Banavali, S., Look, A.T., and Fearon, E.R. (1999) Netrin-1: a candidate DCC ligand is inactivated in a subset of neuroblastomas and brain tumors. *Cell Growth Diff.* **10**: 35-42.

Reyes-Mugica, M., Rieger-Christ, K., Ohgaki, H., **Ekstrand, B.C.**, Helie, M., Kleinman, C., Yahanda, A., Fearon, E.R., Kleihues, P., and Reale, M.A. (1997) Loss of *DCC* expression and glioma progression. *Cancer Res.* **57**: 382-386.

**Ekstrand, B.C.**, Mansfield, T.A., Bigner, S.H., and Fearon, E.R. (1995) *DCC* expression is altered by multiple mechanisms in brain tumours. *Oncogene* **11**: 2393-2402.

Fearon, E.R., **Ekstrand, B.C.**, Hu, G., Pierceall, W.E., Reale, M.A., and Bigner, S.H. (1994) Studies of the deleted in colorectal cancer gene in normal and neoplastic tissues. *Cold Spring Harb. Symp. Quant. Biol.* **59**: 637-643.

Vreman, H.J., **Ekstrand, B.C.**, and Stevenson, D.K. (1993) Selection of metalloporphyrin heme oxygenase inhibitors based on potency and photoreactivity. *Pediatr. Res.* **33**: 195-200.

## ABSTRACTS PRESENTED:

**Ekstrand, B.C.**, Lucas, J.B., Horwitz, S.M., Breslin, S., Bartlett, N.L., Hoppe, R.T., and Horning, S.J. (2002) Rituximab in lymphocyte predominant Hodgkin's disease (LPHD): results of a phase II trial. *Proc. Amer. Soc. Clin. Oncol.* **21**: 264a

**Ekstrand, B.C.**, Bigner, S.H., and Fearon, E.R. (1995) *DCC* gene mutations and loss of expression in glioblastomas. *Proc. Amer. Assoc. Cancer Res.* **36**: 574a.

**Ekstrand, B.C.**, Vreman, H.J., and Stevenson, D.K. (1990) Selection of heme oxygenase inhibitors based on potency and photoreactivity. *Pediatric Res.* **27**: 59a.

**ORAL PRESENTATIONS:**

“Loss of Expression of the *deleted in colorectal cancer (DCC)* gene during tumorigenesis: mechanisms and meanings.” Ph.D. dissertation, Yale University School of Medicine, Department of Pharmacology, June 1997.

“The *DCC* gene and its role in cancer.” Gordon Research Conference on Cell Contact and Adhesion, Andover, New Hampshire, 1995.

**RESEARCH EXPERIENCE:**

Ongoing experience in Phase I, II, III, and IV Clinical Pharmaceutical Trials as a Principal and/or Sub Investigator. To date, involved in over 10 oncology related studies

